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Myocardial MiR-30 downregulation triggered by
doxorubicin drives alterations in β-adrenergic signaling
and enhances apoptosis
L Roca-Alonso*,1, L Castellano*,1, A Mills2, AF Dabrowska1, MB Sikkel2, L Pellegrino1, J Jacob1, AE Frampton1,3, J Krell1, RC Coombes1,
SE Harding2, AR Lyon2,4,5 and J Stebbing1,5
The use of anthracyclines such as doxorubicin (DOX) has improved outcome in cancer patients, yet associated risks of
cardiomyopathy have limited their clinical application. DOX-associated cardiotoxicity is frequently irreversible and typically
progresses to heart failure (HF) but our understanding of molecular mechanisms underlying this and essential for development of
cardioprotective strategies remains largely obscure. As microRNAs (miRNAs) have been shown to play potent regulatory roles in
both cardiovascular disease and cancer, we investigated miRNA changes in DOX-induced HF and the alteration of cellular
processes downstream. Myocardial miRNA profiling was performed after DOX-induced injury, either via acute application to
isolated cardiomyocytes or via chronic exposure in vivo, and compared with miRNA profiles from remodeled hearts following
myocardial infarction. The miR-30 family was downregulated in all three models. We describe here that miR-30 act regulating the
β-adrenergic pathway, where preferential β1- and β2-adrenoceptor (β1AR and β2AR) direct inhibition is combined with Giα-2
targeting for fine-tuning. Importantly, we show that miR-30 also target the pro-apoptotic gene BNIP3L/NIX. In aggregate, we
demonstrate that high miR-30 levels are protective against DOX toxicity and correlate this in turn with lower reactive oxygen
species generation. In addition, we identify GATA-6 as a mediator of DOX-associated reductions in miR-30 expression. In
conclusion, we describe that DOX causes acute and sustained miR-30 downregulation in cardiomyocytes via GATA-6. miR-30
overexpression protects cardiac cells from DOX-induced apoptosis, and its maintenance represents a potential cardioprotective
and anti-tumorigenic strategy for anthracyclines.
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Doxorubicin (DOX) is the most used anthracycline in the
oncology clinic, delivering anti-tumor activity against numerous
types of malignancy.1,2 The exact mechanisms accounting for
the anti-cancer action(s) of anthracyclines remain poorly
understood, although a variety of effects have been proposed,
most notably inhibition of topoisomerase II (Top2).2 Patients
receiving DOX treatment often experience adverse effects, the
most serious being dose-dependent cardiotoxicity that can
lead to heart failure (HF). Efficient prevention and early
diagnosis of DOX-induced cardiotoxicity is essential, as once
patients develop advanced HF, their prognosis is poor.3
Mechanistically, reactive oxygen species (ROS) and oxidative
stress have been linked to DOX-induced cardiotoxicity4,5
and could explain the relative tissue specificity of the adverse
effects of DOXas the heart is rich inmitochondria, metabolically
active and has relatively low antioxidant-producing enzymes.6
Others have highlighted the cardioprotective effects of
cardiomyocyte-specific Top2β deletion, which suggest this
enzyme could mediate the pathological side effects of DOX.7
Alterations in myocardial responses to catecholamines are
well described in HF. Physiologically, β-adrenoceptor (βAR)
activation by catecholamines results in protein G (Gs)-
dependent activation of adenylyl cyclase (AC), enhancing
cyclic adenosine monophosphate (cAMP) production from
ATP. cAMP activates protein kinase A (PKA), which is
responsible for phosphorylating several proteins involved in
Ca2+ metabolism and contraction. Although β1AR is only able
to interact with Gs, β2AR can bind both to Gs and to the
inhibitory Gi protein; β2AR-Gi activation reduces contraction
via both cAMP-dependent and -independent mechanisms.
Chronic sympathetic activation is detrimental for the heart and
sustained overexpression of β1AR triggers myocyte apoptosis
and hypertrophy leading to HF.8 Sustained β-adrenergic
stimulation leads to reduced expression and/or compensatory
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desensitization of βARs to catecholamines, both features of
the functionally impaired heart.9 Increased expression of Gi—
particularly of the α-2 subunit (Giα-2)—is also observed in HF,
where enhanced β2AR-Gi coupling triggers diminished basal
contractility following receptor activation. However, the
mechanisms underpinning Gi upregulation in chronic HF have
remained unknown.10,11 β-Adrenergic antagonists (β-blockers)
constitute a critical clinical advance in the treatment of HF,
being able to improve cardiac output.12,13
Contributing to the developing molecular picture of multiple
diseases, microRNAs (miRNAs) are a class of short
(~22 nucleotides, nt) non-coding RNAs that play influential
roles in the post-transcriptional ‘fine-tuning’ of gene
expression.14 miRNAs are often coded in clusters and
transcribed as single transcriptional units, each forming
a primary miRNA, which is then processed and gives rise to
multiple mature miRNAs.15,16 The miRNA classification into
families groups together those miRNAs that share the same
‘seed region’, which is the sequence necessary for target
messenger RNA (mRNA) recognition and is usually located
between nucleotides 2 and 8.17 miRNAs are implicated in
heart development and function18–20 and specific miRNA
signatures have been associated with certain cardiac
pathologies.21–24 Nonetheless, few studies have validated
their functional impact. Although recent evidence describes
the dysregulation of miRNAs across the heart upon DOX
treatment,25,26 a cardiomyocyte-specific miRNA signature of
DOX-triggered alterations, or their consequences, is currently
lacking.
We identified the DOX-induced cardiomyocyte miRNA
alterations in various models of cardiac toxicity. We then
proceeded to uncover the regulation of pathways implicated in
heart disease by the miR-30 family (miR-30), which we found
to be downregulated by DOX. This miRNA family is formed by
four clusters, located in different genomic regions and
organized in the followingway in both rat and human:miR-30a;
miR-30c-2; miR-30b and miR-30d; miR-30e and miR-30c-1
(http://www.mirbase.org).We report that miR-30 fine-tunes the
β-adrenergic pathway by targeting βARs and Giα-2, while also
inhibiting the expression of the pro-apoptotic gene BNIP3L/NIX.
Overall, gene expression regulation by miR-30 seems to be
protective against the toxic effects of DOX in cardiac cells.
Results
DOX triggers miR-30 family downregulation in cardio-
myocytes. To obtain the miRNA signature of cardiomyo-
cytes affected by DOX treatment, we established both in vitro
and in vivo models. These included two different DOX
treatments: an acute in vitro administration to primary isolated
adult rat ventricular cardiomyocytes (ARVCMs) and an in vivo
model of DOX-induced HF (Supplementary Figures 2 and 3),
created by serial injections of the drug as previously
described.27 An in vivo model of myocardial infarction (MI)
was generated by proximal left anterior descendent (LAD)
coronary artery ligation leading to pathological hypertrophy at
4 weeks and HF by 16–20 weeks and was included as
reference of severe cardiomyopathy.28 A total of 26 miRNAs
had significantly altered expression by ≥ 1.5-folds in DOX-
treated cultured ARVCMs, 18 miRNAs in ARVCMs obtained
from DOX-treated hearts and 40 miRNAs were dysregulated
in ARVCM from infarcted hearts 4 weeks post MI. Seven
miRNAs (miR-133b, miR-143, miR-210, miR-29c, miR-30d,
miR-30e and miR-345-5p) were found to be downregulated in
all three models (Figure 1). A subset of three overlapping hits
(miR-30e, miR-210 and miR-29c) was chosen for validation
by reverse transcription–quantitative PCR (RT-qPCR;
Supplementary Figure 4). Moreover, sustained miRNA
alteration during HF progression was confirmed by RT-qPCR
at a later time of 16–20 weeks post MI stage (Supplementary
Figure 5). We could also confirm aberrant expression of
several miRNAs that had previously linked to heart disease in
our models (Figure 1b, bold writing).21,22,25,29–35 Strikingly,
three members of the miR-30 family (miR-30a, miR-30d and
miR-30e) were downregulated in at least two models, which
indicated potential biological relevance. miR-30e showed the
greatest dysregulation across all three models of study
(Figure 1c).
DOX induces β1AR, β2AR, Giα-2 and BNIP3L/NIX expres-
sion through miR-30 downregulation. To further investi-
gate the implication of miR-30 in DOX-induced myocardial
damage, we used TargetScan software and retrieved a list of
highly conserved predicted miR-30 target genes, based on
seed pairing. Given that all family members share the same
seed sequence, they are predicted to target the same
genes.36 Pathway enrichment analysis of putative miR-30
targets using Database for annotation, visualization and
integrated discovery (http://david.abcc.ncifcrf.gov/) revealed
an implication of this target list in cardiovascular disease,
being 3 out of the 10 most significantly enriched pathways
related to cardiomyopathy (Figure 2a). Among the predicted
miR-30 targets, we focused on four genes, which were
identified as part of an interacting network by Cytoscape
(Supplementary Figure 7) and thus considered high-
confidence predictions. Three of these genes are involved
in the β-adrenergic pathway: β1AR, β2AR and Giα-2. The
fourth target selected was the BCL2/adenovirus E1B-
interacting protein 3-like (BNIP3L or NIX), an important
apoptotic effector capable of mediating mitochondrial death
and triggering myocardial disease37–40 (Figure 2b).
All four targets were first validated by luciferase assays using
vectors containing the respective target 3’UTR downstream of
the luciferase reporter gene (seeMethods).Mutated versions of
the 3’UTR sequenceswith disrupted miR-30-binding sites were
also assayed to confirm specific miRNA–3’UTR interaction and
the non-target programed cell death protein 4 (PDCD4) was
included as additional negative control (NC). As cellular
platform, we used H9c2 cardiac muscle cell line, which retains
numerous features of mature cardiomyocytes and have been
previously used to investigate DOX cardiotoxicity41,42
(Supplementary Figure 6). A significant reduction in luciferase
activity was recorded for all four predicted targets when co-
transfecting with the corresponding 3’UTR vector and the
miR-30e mimic (pre-30e) as representative of the family,
compared with pre-NC. Conversely, as expected, no changes
were observed when co-transfected with the mutated 3’UTR
versions and for PDCD4 (Figure 2c). Overall, we demonstrated
direct regulation of these four genes by miR-30.
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We next overexpressed miR-30e in H9c2 cardiac cultures
and observed a decrease in target mRNA levels of the
selected targets (Figure 3a).Wequantified protein dysregulation
of BNIP3L and Giα-2 by western blotting (Figure 3b) but this
was not possible for β1AR and β2AR as there were no specific
antibodies commercially available.43,44 To partly overcome
this issue, accumulation of cAMP was used as an indicator of
βAR signaling, which validated miR-30 targeting (Figure 4a).
Additional confirmation of miR-30-dependent regulation of
target genes was achieved by miR-30 inhibition using an
in-house sponge vector designed inhibit the entire miR-30
family45 (Figure 3c). In contrast to the results obtained upon
miR-30e overexpression, increased target mRNA and protein
levels were recorded (Figures 3d and e). These data were
replicated independently using a commercial locked nucleic
acid (LNA) construct for whole miR-30 family inhibition
(Supplementary Figures 8 and 9). Remarkably, DOX treatment
of H9c2 cardiac cells triggered an increase in miR-30 target
mRNA levels, which could be fully reversed by simultaneous
overexpression of miR-30 (Figure 3f). This indicates that
mechanistically DOX is able to inducemiR-30 target expression
through miR-30 downregulation. Interestingly, miR-30 target
upregulation also occurred in vivo upon DOX treatment, which
is consistent with the demonstrated miR-30 downregulation
in this disease model (Figure 3g). Together, these data
suggest that β1AR, β2AR, Giα-2 and BNIP3L/NIX are novel
miR-30 targets and that the downregulation of miR-30 by DOX
is responsible for the increase in target gene expression.
Figure 1 miRNA expression dysregulation occurs upon acute and sustained DOX treatment. (a) Experimental design of the models of study included in the miRNA profiling.
DOX-induced HF in vivo model was generated by six i.p. DOX injections (2.5 mg/kg) spread over a fortnight. MI was induced by proximal LAD coronary artery ligation. For acute
DOX treatment, cultured viable ARVCM were treated with 1 μmol/l for 6 h. For all three models, RNA was isolated specifically from viable ARVCM. (b) Venn diagram showing
significantly altered miRNA expression (41.5-folds, Po0.05) detected for the profiled models of cardiac injury (n= 3 per group). The three downregulated members of the
miR-30 family are highlighted in yellow. Several other miRNAs have previously been linked to heart disease when dysregulated in the same direction as we observed and appear
in bold writing. (c) miRNAs that presented reduced expression levels in at least two experimental models. rno, rattus norvegicus.
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miR-30 expression attenuates the contractile response of
cardiomyocytes to βAR stimulation. miRNAs can mod-
ulate the expression of hundreds of mRNAs and is the global
regulatory effect on targets with opposing functions that will
ultimately influence cellular phenotypes. After validating three
members of the β-adrenergic pathway (β1AR, β2AR and Giα-2)
as miR-30 targets, we evaluated the net effects of miR-30
dysregulation on this pathway. As mentioned, cAMP is
Figure 2 miR-30 target prediction and validation of direct 3′UTR regulation by 3’UTR luciferase assay. (a) Pathway enrichment analysis of the predicted miR-30 targets by
TargetScan; performed using Database for annotation, visualization and integrated discovery. Three types of cardiomyopathy are part of the top 10 most significantly enriched
pathways. (b) Representation of miR30e-mRNA annealing for four of the target genes predicted by TargetScan (β1AR, β2AR, BNIP3L and Giα-2). miRNA seed sequence is
highlighted in red. (c) Relative luciferase activity measured on H9c2 cultures, after 24 h of co-transfection with either pre-30e or pre-NC (100 nmol/l) and the correspondent (wild
type (WT) or mutant (mut)) 3′UTR luciferase reporter vector for each of the potential targets. The non-target programed cell death protein 4 (PDCD4) was included as negative
control. Averaged (±S.E.M.) values are the result of at least three independent transfections (ns, not significant; t-test)
Figure 3 Experimental confirmation of β1AR, β2AR, BNIP3L and Giα-2 as miR-30 targets. (a) RT-qPCR shows relative target expression levels when overexpressing
miR-30. All values are normalized to U6 levels and presented as ratios to the pre-NC-transfected controls (20 nmol/l). Three biological replicates were performed on H9c2
cultures. (b) Relative protein levels of BNIP3L and Giα-2 were measured by western blot; band densitometry was quantified by ImageJ and normalized to tubulin. (c) Schematic
view of the sponge vector designed for miR-30 family inhibition (pEGFP-sp30), using the pEGFP-C1 plasmid as backbone. EGFPexpression in transfected cultures was detected
by microscopy. (d) Relative target mRNA levels measured by RT-qPCR and protein levels (e) upon transfection with pEGFP-sp30 for miR-30 family inhibition, or the control vector
pEGFP-C1. Data are averages of three biological replicates performed on H9c2 cardiac cells. (f) Target expression levels measured by RT-qPCR following DOX treatment
(1 μmol/l, 18 h), alone or in combination with miR-30e overexpression (pre-30e transfection). Three independent replicates were performed on H9c2 cells, being presented as
averaged ratio to control ±S.E.M. (g) RT-qPCR data showing expression levels of the predicted miR-30 targets in vivo in DOX-treated hearts (15 mg/kg cumulative dose, n= 5
rats per group). Student’s t-test performed for statistical analysis. Error bars represent± S.E.M.
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a direct indicator of βAR activation while inversely correlates
with Gi activity. We observed significantly increased cAMP
generation upon acute DOX treatment, as well as following
miR-30 inhibition with our pEGFP-sp30 vector. On the other
hand, less cAMP accumulation was detected when over-
expressing miR-30e in cardiac cultures (Figure 4a). These
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findings are consistent with the regulation of βARs by miR-30
and suggest that miR-30 exerts a greater inhibitory effect on
βARs rather than Giα-2.
Having assessed the alterations that miR-30 expression
modulation has on cellular cAMP, we wished to determine the
global effects of miR-30 target regulation on cardiomyocyte
contractility. We transfected primary isolated ARVCM with
miR-30e mimics to achieve overexpression (Supplementary
Figure 10) and recorded single-cell contractility using IonOptix.
No significant changes were observed in the baseline
percentage of contraction amplitude (Figure 4b). We then
stimulated transfected ARVCMwith increasing concentrations
of isoproterenol, a βAR agonist, and analyzed paced
contractile responses. Cells overexpressing miR-30e showed
decreased contractile response to isoproterenol compared
with control cells (Figure 4c), a finding supported by the cAMP
accumulation data.
miR-30 expression is protective against DOX toxicity. It
is known that DOX induces cellular toxicity mediated by
caspase-dependent apoptosis.46 We investigated whether
miR-30 expression modulation is sufficient to affect DOX-
induced toxicity in cultured cardiac cells. We measured the
activity of caspases 3 and 7 as apoptotic indicator.
Ectopically increased miR-30e expression resulted in
reduced apoptosis, bringing caspase activity closer to the
levels observed upon vehicle treatment (Figure 5a). On the
contrary, cultures presented higher caspase activity when
inhibiting miR-30 with our pEGFP-sp30 sponge vector
(Figure 5a).
DOX has also been described to increase the expression of
Bax (pro-apoptotic gene) and to decrease Bcl-2 (anti-
apoptotic gene) levels. Indeed, elevated Bax/Bcl-2 ratio
increases susceptibility to death following apoptotic stimuli47
and restored Bcl-2 expression has been shown to protect
cardiomyocytes against DOX toxicity.48 To further assess the
protective effects of miR-30 against DOX insult, we measured
the Bax/Bcl-2 expression ratio in treated cardiac cultures. As
expected, DOX treatment progressively increased the Bax/Bcl-2
ratio. In contrast, miR-30e overexpression reduced theBax/Bcl-2
Figure 4 miR-30 effects on cAMP accumulation and contractility. (a) cAMP accumulation data expressed as % of the respective control samples. Values are the mean±S.E.M.
of three independent experiments. The diagram on the right shows the contribution to cAMP production of the three miR-30 targets involved in the β-adrenergic pathway.
(b) Baseline % of contraction amplitude of paced ARVCM transfected with either pre-30e or pre-NC for 48 h (100 nmol/l), measured using IonOptix (n= 8–10 cells from 6
preparations; t-test; ns, not significant). (c) Contractile responses of isoproterenol-stimulated transfected ARVCM, recorded using IonOptix (n= 6 cells from 6 preparations, F-test)
Figure 5 High miR-30 levels are protective against DOX insult and reduce ROS generation. (a) Left graph: caspase activity in cardiac cultures treated with DOX alone
(1 μmol/l, 18 h) and in combination with miR-30e overexpression through pre-30e mimic transfection (20 nmol/l). Right graph: relative caspase activity upon miR-30 family
inhibition using the pEGFP-sp30 sponge vector. (b) Bax and Bcl-2 protein levels measured by western blot analysis. Cells were treated with DOX (1 μmol/l, 6 h and 18 h) and also
transfected with pre-30e mimics (20 nmol/l) in combination with DOX (1 μmol/l, 18 h). Band densitometry was measured using Image J. All values are normalized to Tubulin and
expressed as Bax/Bcl-2 ratio. (c) ROS generation of transfected cultures for miR-30 overexpression or inhibition, measured by DCFDA fluorescence intensity. All assays (a, b, c)
were performed on H9c2 cells and results are average of independent triplicates ± S.E.M. (t-test; ns, not significant)
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ratio upon DOX treatment (Figure 5b). An additional char-
acteristic of DOX-associated cardiomyocyte damage is high
ROS levels.49 We therefore assessed the impact of miR-30 on
ROS. Notably, cells with high miR-30e expression showed
reduced ROS, whereas miR-30 inhibition resulted in higher
ROS levels. No further increase in ROS production was
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observed when combining DOX treatment and miR-30
inhibition (Figure 5c). This finding further confirmed the benefit
of high miR-30 expression in cardiac cells.
GATA-6 mediates DOX-induced miR-30 downregulation.
We next wished to establish the mechanism via which DOX
downregulates miR-30 expression. GATA-6 is a transcription
factor highly expressed in the heart and known to play a key
role in cardiac development.50 Interestingly, we discovered
evidence of GATA-6 binding to miR-30 cluster promoters by
data mining of chromatin immunoprecipitation sequencing
experiments, using deepBase (http://deepbase.sysu.edu.cn/).
Strikingly, we identified increased GATA-6 levels shortly
(30 min–1 h) in primary isolated ARVCM after DOX treatment,
accompanied by a sustained reduction in mature miR-30e
expression from the 1 h time point (Figure 6a).
We silenced GATA-6 using RNA interference
(Supplementary Figure 12) and, in order to unveil the nature
of its regulatory effect, we quantified primary and mature
miR-30 levels of two family members coded in different
clusters (miR-30d, miR-30e) by RT-qPCR. GATA-6 inhibition
resulted in increased levels of miR-30d and miR-30e, at both
the primary and mature stages of their bioprocessing
(Figure 6b), suggesting an inhibitory role for GATA-6 on the
miR-30 promoters. Subsequently, we measured expression
levels of the validated miR-30 targets (β1AR, β2AR, Giα-2 and
BNIP3L) upon GATA-6 silencing, which were accordingly
reduced (Figure 6c). Decreased target expression levels could
be compensated by simultaneous miR-30 family inhibition
using LNA oligonucleotides (Figure 6c), suggesting a direct
mediation of the GATA-6 effects on target gene expression by
miR-30. Finally, in order to determine the impact of GATA-6 on
cell toxicity, we measured caspase activity in treated H9c2
cardiac cultures. GATA-6 inhibition was reduced activation of
apoptotic pathways even in the presence of DOX administration
(Figure 6d).
Discussion
We describe here cardiomyocyte-specific alterations in
miRNA expression following acute and chronic DOX injury,
and post-MI induction. A shared miRNA subset was detected
across the assayed models of cardiac toxicity, reflective of
Figure 6 GATA-6 mediates miR-30 downregulation triggered by DOX. (a) RT-qPCR data showing GATA-6 and miR-30e expression levels in response to DOX time-course
treatment (1 μmol/l). (b) Relative levels of primary and mature miR-30d and miR-30e, upon GATA-6 silencing detected by RT-qPCR. (c) RT-qPCR data for miR-30 target mRNA
levels in response to GATA-6 silencing (25 nmol/l, 72 h) and after co-transfection with compensatory LNA miR-30 family inhibitors (100 nmol/l, 72 h). (d) Relative caspase activity
in response to GATA-6 silencing, ±DOX treatment (1 μmol/l, 18 h). All values (a, b, c, d) were obtained performing biological triplicates on H9c2 cells and are presented as
averaged ratio to the respective control± S.E.M. All RT-qPCR results were normalized to the correspondent U6 Ct value (ns, not significant; t-test)
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consistencies in the cardiomyocyte response to injury.
However, those miRNAs only differentially expressed in
response to acute and/or sustained DOX treatments also
suggest the existence of unique molecular signatures in
anthracycline-related myocardial damage (Figure 1b). We
believe that the rapid alteration of these miRNAs within hours
of exposure to DOX and maintained over time could be of
translational relevance, both as diagnostic biomarker and as
therapeutic strategy.
In particular, we describe here the myocardial downregula-
tion of several miR-30 family members by acute and sustained
DOX treatment and validate four essential genes for cardio-
myocyte biology as novel miR-30 targets (β1AR, β2AR, Giα-2
andBNIP3L/NIX; Figures 2c and 3). These data are consistent
with our previous findings in which miRNAs often target
multiple members of a shared signaling pathway, as individual
target inhibition in vivo is unlikely to be complete.51 Alterations
in several of these genes have previously been linked to HF
(i.e., desensitized βARs, chronic β1AR activation and
increased Giα-2 expression).
9,10 Moreover, the pro-apoptotic
target gene BNIP3L/NIX has been linked to cardiomyopathy
through mitochondrial cell death.39,52 In concordance with the
present data (Figure 3g), enhanced β2AR cardiac expression
upon DOX treatment in vivo has recently been reported,
although the mechanisms involved were not investigated.53
Moreover, β2AR deletion has been shown to prevent
cardiomyopathy.54
Reduced miR-30 levels have been associated with
myocardial matrix remodeling and with angiotensin II-induced
hypertrophy.31,55 Low miR-30e expression was also detected
in myocardial tissue from patients with dilated cardiomyopathy
and aortic stenosis.56 However, the specific myocardial
expression of miR-30 in the context of exposure to DOX and
its downstream mechanisms had not been previously demon-
strated. We show that high miR-30 levels are connected to a
global decrease in cAMP (Figure 4a), likely to be advanta-
geous given the described link between high cAMP/PKA and
cardiomyocyte death.57 The greater accumulation of cAMP
triggered by acute DOX treatment than by specific miR-30
inhibition alone raises the hypothesis that DOX may be acting
through alternate pathways toward the same detrimental
effect. Upon miR-30e overexpression, ARVCM presented
decreased contractile responses to isoproterenol stimulation.
As βAR and Giα-2 have opposing effects on the same pathway,
such attenuated contractile response reveals a phenotype
suggesting preferential βAR repression alongside a compen-
satory inhibition of Giα-2 (Figures 4a and c, Supplementary
Figure 11). This negative feedback loop is likely to contribute
to the fine-tuning of the system, which is characteristic of
miRNAs and allows intensive regulation of complex biological
processes.58 The preferential βAR inhibition observed results
in an overall effect simulating β-blocker agents, which are
commonly used to treat HF. Furthermore,milder Giα-2 targeting
by miR-30 could also tentatively be beneficial, as retention of
Gi activity serves to reduce myocyte death.
59
For the first time, we show that DOX treatment triggers an
early induction of GATA-6 expression. In addition, our data
suggest that DOX-induced GATA-6 upregulation represses
miR-30 transcription, a model supported by (primary and
mature) miR-30 upregulation in response to GATA-6 silencing.
In keeping with this, miR-30-dependent target downregulation
was observed upon GATA-6 inhibition (Figure 6).
Cardiomyocyte apoptosis, involving cytochrome c and
caspase activation, is a crucial event in HF development in
general and after DOX injury.46,60,61 Importantly, high miR-30
levels are protective against DOX insult while inhibition of
miR-30 is sufficient to increase caspase-mediated apoptosis
(Figure 5a). Consistent with this, the Bax/Bcl-2 ratio was lower
in cardiac cultures overexpressing miR-30e upon DOX
administration (Figure 5b) and ROS generation inversely
correlated with miR-30 levels, further indicating the beneficial
effects of miR-30 expression for cardiac cell viability
(Figure 5c).
Interestingly, β-blockers have been shown to prevent
cancer progression both in patient cohorts62,63 and animal
models.64–66 Moreover, increasing evidence indicates
a tumor-suppressor role for miR-30, having been shown to
minimize resistance to chemotherapy and to correlate with
less invasive tumors.67–70 We confirmed this finding in our
system by Transwell migration assays performed on the
highly metastatic breast cancer cell line MDA-MB-231, which
had impaired migration upon miR-30 overexpression
(Supplementary Figure 13). In addition, analyses of breast
cancer patients’ data freely available at the Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) consistently
showed a reduction in miR-30 levels compared with control
individuals (Supplementary Figure 14). Similarly, both Surv-
Micro (http://bioinformatica.mty.itesm.mx/SurvMicro) and
PROGmiR (http://www.compbio.iupui.edu/progmir) prognos-
tic databases indicated high miR-30 expression to be
a biomarker of good prognosis in breast cancer
(Supplementary Figure 15). These data are encouraging
and suggest that controlled administration of miR-30 mimics
could deliver a pleiotropic therapeutic effect. Unfortunately, we
could not carry out the required experiments to investigate this
further due to the restrictions applied on animal experimentation
by the UK Home Office.
In aggregate, our findings should contribute to unraveling
the complex web of mechanisms via which DOX is able to
cause cardiac toxicity and dysfunction, as we reveal the
targeting of pathways involved in cardiomyocyte function and
viability by a miRNA family that is altered by DOX (Figure 7).
Materials and Methods
Animal models. All animal surgical procedures and perioperative management
were carried out in accordance with the United Kingdom Home Office Guide on the
Operation of Animals (Scientific Procedures) Act 1986 by licensed personnel. See
Supplementary Information for details of the experimental procedures.
MI induction: Adult male Sprague–Dawley rats (250–300 g) underwent proximal
LAD coronary artery ligation to induce chronic MI as previously described by our
group.28 Animals were anesthetized with 5% isofluorane in O2 and maintained on
1.5% isofluorane during surgery. 0.05% buprenorphine and 5 mg/kg enrofloxacil
were administered intraperitoneally to prevent pain and infection. Two infarcted
cohorts were generated. To model early post MI-hypertrophy, animals were killed
4 weeks after MI induction (n= 5). Late-stage HF model hearts were explanted and
prepared for cell isolation 16–20 weeks post MI surgery (n= 5), when an advanced
HF phenotype was established.28 Age-matched controls (AMCs, n= 5 for each)
were used in both cases to preserve animal welfare.
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DOX-induced HF model: Adult male Sprague–Dawley rats (250–300 g) were
administered a total cumulative dose of 15 mg/kg of DOX delivered via six
intraperitoneal injections over 2 weeks (n= 5). Each injection contained 2.5 mg/kg
of DOX (Teva, Castleford, UK) diluted in saline up to a volume of 2 ml. AMC rats
were used as controls (n= 5). Animals were kept under constant monitoring for
signs of HF and any other possible adverse effects. Three weeks after the last
injection, animals were killed and hearts explanted, weighed and prepared for cell
isolation.
Ventricular cardiomyocyte isolation. Ventricular cardiomyocyte isolation
from adult Sprague–Dawley rat hearts was carried out via serial enzymatic
collagenase-hyaluronidase digestion as described previously28 (see Supplementary
Information).
Cell culture and treatments. Adult rat ventricular cardiomyocytes (ARVCM)
were maintained in supplemented M199 (Invitrogen, Paisley, UK). ARVCM from
AMC animals or DOX/4week post-MI models were plated in laminin (Invitrogen)-
coated six-well plates and viable rod-shaped cells were allowed to attach for an
hour. Apoptotic floating ARVCM were then discarded. For in vitro studies, medium
was renewed and DOX (Teva) was then administered to cultured viable ARVCM.
A clinically relevant concentration of 1 μmol/l was used throughout.6 This dose was
allowed to act in the cultures for 6 h for miRNA expression level check. For
evaluation of gene expression changes (mRNA and protein), DOX treatments were
conducted over 18 h. Control wells were treated with the same volume of vehicle
(saline). H9c2 cardiac muscle cells were used as model to overcome the limitations
of ARVCM,41 and were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum, 1% penicillin/streptomycin and 2%
L-glutamine.
Transfections. H9c2 cells were plated at 40% confluence in six-well plates and
transfected on the following day and for 72 h, with 20 nmol/l of precursor miRNAs for
mimicry overexpression (pre-30e or pre-NC; Applied Biosystems, Paisley, UK) and
100 nmol/l of miRCURY LNA for family inhibition (Exiqon, Vedbaek, Denmark),
using HiPerFect transfection reagent (Qiagen, West Sussex, UK). For sponge vector
transfections (pEGFP-sp30 or pEGFP-C1 control), we used Lipofectamine 2000
(Life Technologies Ltd, Paisley, UK) on 90% confluent cultures and allowed them to
get transfected for 48 h in antibiotic-free medium. For luciferase assays, H9c2 cells
were plated at a density of 50 000 cells/well in 24-well plates and co-transfected the
following day with 100 nmol/l of pre-30e/pre-NC and 100 ng of the respective
pLightSwitch_3′UTR GoClone for each target 3’UTR, also using Lipofectamine
2000. In each independent replicate, three wells were transfected for each condition.
For contractility studies, primary isolated ARVCM were transfected in six-well plates
and kept in solution for 48 h. We used Lipofectamine 2000 (Life Technologies Ltd)
and a molarity of 100 nmol/l of pre-30e or pre-NC.
Sponge plasmid construction. The pEGFP-sp30 sponge vector was
manufactured by annealing, purifying and cloning primers coding for six bulged
tandem repeats of mismatched miR-30-binding sites. The insert was cloned into the
pEGFP-C1 plasmid (Clontech, Mountain View, CA, USA) using the HindIII and
BamHI restriction sites, as 3’UTR of the EGFP-coding sequence. The generated
sponge vector was then verified by sequencing. Primers used for sponge vector
construction are described in Supplementary Table 1.
miRNA profiling. miRNA profiling was performed using nCounter Rat miRNA
Expression Assay (NanoString Technology, Seattle, WA, USA), using 150 ng of total
RNA. Biological triplicates were assayed for all conditions. Background removal was
performed following the producer’s instructions and quantile normalization of raw
data was carried out using Partek Genomic suite (St. Louis, MO, USA). A list of the
20 most significantly dysregulated hits for each model including P values and fold
Figure 7 Proposed model: importance of the miR-30 regulatory effects in cardiomyocytes following DOX exposure. Upon DOX treatment, there seems to be an acute
increase of GATA-6 expression in cardiomyocytes. GATA-6 is able to repress miR-30 family expression, resulting in DOX-induced miR-30 downregulation. In turn, the expression
levels of miR-30 targets are upregulated. Three of the miR-30 target genes are involved in the complex catecholamine/adrenergic pathway. A correct equilibrium of members is
crucial in this signaling cascade, as AC-cAMP-PKA activation promotes cardiomyocyte contraction, whereas Gi impairs contraction but protects against apoptosis via
Phosphoinositide 3-kinase/Protein kinase B. In addition, miR-30 represses BNIP3L, which is involved in mitochondrial death. miR-30 expression seems to be essential in
regulating mitochondrial apoptotic pathways and it is able to partially counteract DOX-induced toxicity. Solid lines: previously described mechanisms, dashed lines: novel
mechanisms
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changes can be observed in Supplementary Table 3. The full list of assayed miRNA
sequences and complete raw data has been deposited at Gene Expression
Omnibus (GSE36239).
3′UTR Luciferase assays. After 24 h of co-transfection, cells were lysed
using passive lysis buffer (Promega, Madison, WI, USA) and luciferase activity was
detected using LightSwitch Assay System reagent (Switchgear Genomics, Menlo
Park, CA, USA), in a GLOMAX 96 Microplate luminometer (Promega). The 3’UTR-
Luc vectors used were β1AR (S812620), β2AR (S804637), BNIP3L (S812956)
and Giα-2 (S807754), all from Switchgear Genomics. For 3’UTR site-directed
mutagenesis of these vectors, we used the QuickChange II or II XL Site-Directed
Mutagenesis Kit (Agilent Technology, Edinburgh, UK) according to the manufac-
turer’s instructions. The sequences of the plasmid used for this protocol
are reported in Supplementary Table 2. All resulting plasmids were verified
by sequencing.
cAMP accumulation. Treated H9c2 cells were lysed using 0.1 mol/l HCl. The
lysates were then assayed using the 96-well strip cAMP EIA kit (Cayman Chemical,
Ann Arbor, MI, USA) and analyzed according to the manufacturer’s instructions. At
least duplicate wells were included for each sample to account for technical
variability.
Caspase assays. Apoptosis in treated H9c2 cultures was measured by
quantifying caspase 3 and caspase 7 activities, according to the manufacturers’
instructions (Caspase-Glo 3/7 Assay, Promega). Briefly, both medium and cells were
collected from each well and 50 μl of cell suspension were transferred to a 96-well
plate in duplicate. 100 μl of Caspase-Glo reagent were then mixed into each well an
incubated for 1 h at room temperature, before reading luminescence intensity using
a PHERAstarPlus machine (BMG Labtech, Aylesbury, UK). Luminescence value for
caspase activity was normalized to protein content.
ROS detection. Levels of ROS generation in the cultures were measured by
using the MitoScience DCFDA Cellular ROS Detection Assay Kit (Abcam Plc.,
Cambridge, UK), according to the manufacturer’s instructions. Fluorescence
readings were performed in 96-well microplates, using a PHERAstarPlus machine.
Contractility of transfected ARVCM. Following 48 h of pre-miR-30e/NC
transfection, ARVCM in suspension were transferred into a Perspex bath using
a glass coverslip as base. Cells were superfused with KH solution (1 mmol/l Ca2+) at
37 °C, equilibrated with 95% O2/5% CO2. An inverted microscope was used for
imaging and myocytes were electrically stimulated at 0.5 Hz, measuring cell shortening
with the IonOptix system. Values were presented as % contraction amplitude.
Cardiomyocytes from six different preparations were used for each treatment.
Statistical analysis. Unless differently stated, data are presented as
mean±S.E.M. calculated using Prism 5 (GraphPad Software Inc.) and Student’s
t-test was used for value comparison, being Po0.05 considered as significance
threshold. To analyze the contractile responses of ARVCM to increasing
concentrations of isoproterenol, F tests were performed.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We thank Mr. Peter O’Gara for cardiomyocyte cell
isolation. This work was supported by the British Heart Foundation (BHF) [WSCC
G00000 164104 (LRA) and Intermediate Clinical Research Fellowship (ARL)], the
Wellcome Trust (MBS), the Imperial College Trust and Healthcare Charity, Action
Against Cancer, the NIHR and the AICR along with the Imperial ECMC and BRC. The
funders had no role in the study design, data collection and analysis, decision to
publish or preparation of the manuscript.
1. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19:
670–686.
2. Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor
effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol
1999; 57: 727–741.
3. Hjalmarson A, Waagstein F. The role of [beta]-blockers in the treatment of cardiomyopathy
and ischaemic heart failure. Drugs 1994; 47: 31–40.
4. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I.
Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261:
3060–3067.
5. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T et al. p53
Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for
chemotherapy-induced cardiac injury. PLoS ONE 2011; 6: e18005.
6. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances
and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev
2004; 56: 185–229.
7. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF et al. Identification of the molecular
basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18: 1639–1642.
8. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in
β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96: 7059–7064.
9. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart
failure? Circ Res 93: 896–906.
10. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A et al. Increased
messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human
end-stage heart failure. Circ Res 1992; 70: 688–696.
11. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL et al.
Increase of the 40,000- mol wt pertussis toxin substrate (G protein) in the failing
human heart. J Clin Invest 1988; 82: 189–197.
12. Eichhorn EJ. The paradox of β-adrenergic blockade for the management of congestive heart
failure. Am J Med 1992; 92: 527–538.
13. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic
receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–1036.
14. Bartel D. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.
15. Marco A, Ninova M, Ronshaugen M, Griffiths-Jones S. Clusters of microRNAs emerge by
new hairpins in existing transcripts. Nucleic Acids Res 2013; 41: 7745–7752.
16. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:
281–297.
17. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:
15–20.
18. Chen J-F, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z et al. Targeted deletion of
Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA
2008; 105: 2111–2116.
19. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM et al.
Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac
remodeling. Circulation 2008; 118: 1567–1576.
20. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN et al. Dysregulation of
cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129:
303–317.
21. van Rooij E. A signature pattern of stress-responsive microRNAs that can evoke cardiac
hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103: 18255–18260.
22. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW et al. MicroRNAs in the
Human Heart. Circulation 2007; 116: 258–267.
23. van Rooij E, Sutherland L, Qi X, Richardson J, Hill J, Olson E. Control of stress-dependent
cardiac growth and gene expression by a microRNA. Science 2007; 316: 575–579.
24. Dong D-L, Chen C, Huo R, Wang N, Li Z, Tu Y-J et al. Reciprocal repression between
microRNA-133 and calcineurin regulates cardiac hypertrophy. Hypertension 2010; 55:
946–952.
25. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S et al. Acute doxorubicin
cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB
pathway. Cardiovasc Res 2010; 87: 656–664.
26. Vacchi-Suzzi C, Bauer Y, Berridge BR, Bongiovanni S, Gerrish K, Hamadeh HK et al.
Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment. PLoS One
2012; 7: e40395.
27. Siveski-Iliskovic N, Kaul N, Singal P. Probucol promotes endogenous antioxidants and
provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89:
2829–2835.
28. Lyon AR, MacLeod KT, Zhang Y, Garcia E, Kanda GK, Lab MJ et al. Loss of T-tubules and
other changes to surface topography in ventricular myocytes from failing human and
rat heart. Proc Natl Acad Sci 2009; 106: 6854–6859.
29. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al.
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac
fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027–13032.
30. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes
to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456:
980–984.
31. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I et al. miR-133
and miR-30 regulate connective tissue growth factor. Circ Res 104: 170–178.
32. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P et al. MicroRNA-133 controls
cardiac hypertrophy. Nat Med 2007; 13: 613–618.
33. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA et al. MicroRNA-210 as a novel therapy for
treatment of ischemic heart disease. Circulation 2010; 122: S124–S131.
miR-30 and anthracycline cardiomyopathy
L Roca-Alonso et al
11
Cell Death and Disease
34. Shieh JTC, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac
stress response. PLoS One 2011; 6: e19481.
35. Wang G-K, Zhu J-Q, Zhang J-T, Li Q, Li Y, He J et al. Circulating microRNA: a novel
potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J
31: 659–666.
36. Lewis B, Burge C, Bartel D. Conserved seed pairing, often flanked by adenosines, indicates
that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.
37. Chen Y, Lewis W, Diwan A, EH-Y Cheng, Matkovich SJ, Dorn GW. Dual autonomous
mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy.
Proc Natl Acad Sci USA 2010; 107: 9035–9042.
38. Ding W-X, Ni H-M, Li M, Liao Y, Chen X, Stolz DB et al. Nix is critical to two distinct phases
of mitophagy, reactive oxygen species-mediated autophagy induction and parkin-ubiquitin-
p62-mediated mitochondrial priming. J Biol Chem 2010; 285: 27879–27890.
39. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW. Nix-Mediated
apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation.
Circulation 117: 396–404.
40. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC et al. Mitochondrial
death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy.
Nat Med 2002; 8: 725–730.
41. L'Ecuyer T, Horenstein MS, Thomas R, Vander Heide R. Anthracycline-induced cardiac
injury using a cardiac cell line: potential for gene therapy studies. Mol Genetics Metab 2001;
74: 370–379.
42. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. Morphological,
biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from
rat heart. Circ Res 1991; 69: 1476–1486.
43. Hamdani N, Velden J. Lack of specificity of antibodies directed against human beta-
adrenergic receptors. Naunyn Schmiedeberg Arch Pharmacol 2009; 379: 403–407.
44. Pradidarcheep W, Stallen J, Labruyère W, Dabhoiwala N, Michel M, Lamers W. Lack of
specificity of commercially available antisera against muscarinergic and adrenergic
receptors. Naunyn Schmiedeberg Arch Pharmacol 2009; 379: 397–402.
45. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in
mammalian cells. Nat Meth 2007; 4: 721–726.
46. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo
causes cytochrome c release and cardiomyocyte apoptosis, as well as increased
mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax Ratio. Cancer Res
2002; 62: 4592–4598.
47. Oltval ZnN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved
homolog, Bax, that accelerates programed cell death. Cell 1993; 74: 609–619.
48. Lv X, Yu X, Wang Y, Wang F, Li H, Wang Y et al. Berberine inhibits doxorubicin-triggered
cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2
expression. PLoS One 2012; 7: e47351.
49. Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L et al. Role of
superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and
in vitro. Am J Physiol Heart Circ Physiol 2009; 296: H1466–H1483.
50. Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5, and -6: ubiquitously
expressed regulators of tissue-specific gene expression. J Biol Chem 2000; 275:
38949–38952.
51. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J et al. MicroRNAs
cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor
growth and progression. Gastroenterology 2014; 146: 268–277 e18.
52. Chen Y, Lewis W, Diwan A, Cheng EHY, Matkovich SJ, Dorn GW. Dual autonomous
mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy.
Proc Natl Acad Sci 2010; 107: 9035–9042.
53. Merlet N, Piriou N, Rozec B, Grabherr A, Lauzier B, Trochu J-N et al. Increased beta2-
adrenoceptors in doxorubicin-induced cardiomyopathy in rat. PLoS One 2013; 8: e64711.
54. Fajardo G, Zhao M, Urashima T, Farahani S, Hu D-Q, Reddy S et al. Deletion of the β2-
adrenergic receptor prevents the development of cardiomyopathy in mice. J Mol Cell Cardiol
2013; 63: 155–164.
55. Pan W, Zhong Y, Cheng C, Liu B, Wang L, Li A et al. MiR-30-regulated autophagy mediates
angiotensin II-induced myocardial hypertrophy. PLoS One 2013; 8: e53950.
56. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD et al. Altered microRNA expression
in human heart disease. Physiol Genomics 2007; 31: 367–373.
57. Zhu W-Z, Wang S-Q, Chakir K, Yang D, Zhang T, Brown JH et al. Linkage of β1-adrenergic
stimulation to apoptotic heart cell death through protein kinase A‚Äìindependent activation of
Ca2+/calmodulin kinase II. J Clin Invest 2003; 111: 617–625.
58. van Rooij E, Marshall WS, Olson EN. Toward MicroRNA–Based Therapeutics for Heart
Disease: The Sense in Antisense. Circ Res 2008; 103: 919–928.
59. Zhu W-Z, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao R-P. Dual modulation of cell
survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes.
Proc Natl Acad Sci USA 2001; 98: 1607–1612.
60. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicin-
induced apoptosis. Biochim Biophys Acta 2002; 1588: 94–101.
61. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD et al. Apoptosis in heart
failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human
cardiomyopathy. Proc Natl Acad Sci USA 1999; 96: 8144–8149.
62. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast
cancer mortality: a population- based study. J Clin Oncol 2011; 29: 2635–2644.
63. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F et al.
Beta-Blocker use is associated with improved relapse-free survival in patients with triple-
negative breast cancer. J Clin Oncol 2011; 29: 2645–2652.
64. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A et al. Behavioral stress
accelerates prostate cancer development in mice. J Clin Invest 2013; 123: 874–886.
65. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V et al. The
sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer
Res 2010; 70: 7042–7052.
66. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS et al. The norepinephrine-
driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is
inhibited by β-blockers. Int J Cancer 2006; 118: 2744–2749.
67. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A et al. miR-30 as a tumor suppressor
connects EGF/Src signal to ERG and EMT. Oncogene 2013.
68. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K et al. MicroRNA-30c inhibits
human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun
2013; 4: 1393.
69. Yu F, Deng H, Yao H, Liu Q, Su F, Song E.. Mir-30 reduction maintains self-renewal and
inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29: 4194–4204.
70. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z et al. MicroRNA-30a suppresses breast
tumor growth and metastasis by targeting metadherin. Oncogene 2013; 33: 3119–3128.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
miR-30 and anthracycline cardiomyopathy
L Roca-Alonso et al
12
Cell Death and Disease
